Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-02-20

AUTHORS

Janice P. Dutcher, Paul de Souza, David McDermott, Robert A. Figlin, Anna Berkenblit, Alexandra Thiele, Mizue Krygowski, Andrew Strahs, Jay Feingold, Gary Hudes

ABSTRACT

Purpose Exploratory subgroup analyses from the phase 3 global advanced renal cell carcinoma (ARCC) trial were conducted to assess the influence of tumor histology on outcome of patients treated with temsirolimus (Torisel™) or interferon-α (IFN). Patients and methods Patients with ARCC including clear cell and other types such as papillary and chromophobe histologies received either IFN (3 million units [MU] subcutaneously three times weekly, escalating to 18 MU) or temsirolimus (25 mg intravenously weekly). Results Approximately 80% of patients had clear cell and 20% of patients had other histologies, the majority of which were papillary. Patients with clear cell and other RCC histologies, treated with temsirolimus, demonstrated comparable median overall and progression-free survival. In contrast, patients with other RCC histologies, treated with IFN, demonstrated shorter median overall and progression-free survival than patients with clear cell RCC. Hazard ratios for death for treatment with temsirolimus versus IFN were less than 1 for patients regardless of tumor histology. For patients treated with temsirolimus, 59% with clear cell and 68% with other RCC histologies experienced tumor reductions. For patients treated with IFN, 35% with clear cell and 14% with other RCC histologies had tumor reductions. However, temsirolimus did not appear to improve the objective response rate compared to IFN. Temsirolimus resulted in a superior clinical benefit rate compared with IFN, regardless of tumor histology. Conclusion Temsirolimus appears to be efficacious in patients with clear cell and non-clear cell histologies and can, therefore, be used for the treatment of all types of RCC. More... »

PAGES

202-209

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-009-9177-0

DOI

http://dx.doi.org/10.1007/s12032-009-9177-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015825260

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19229667


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sirolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Montefiore Medical Center-North Division/New York Medical College, 600 East 233rd Street, 10466, Bronx, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.240283.f", 
          "name": [
            "Montefiore Medical Center-North Division/New York Medical College, 600 East 233rd Street, 10466, Bronx, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dutcher", 
        "givenName": "Janice P.", 
        "id": "sg:person.0760406720.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760406720.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, St. George Hospital, 2217, Kogarah, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.416398.1", 
          "name": [
            "Department of Medical Oncology, St. George Hospital, 2217, Kogarah, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Souza", 
        "givenName": "Paul", 
        "id": "sg:person.0762337214.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762337214.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Beth Israel Deaconess Medical Center, 02215, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.239395.7", 
          "name": [
            "Department of Oncology, Beth Israel Deaconess Medical Center, 02215, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McDermott", 
        "givenName": "David", 
        "id": "sg:person.0656541200.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656541200.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 91010, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Division of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 91010, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Figlin", 
        "givenName": "Robert A.", 
        "id": "sg:person.0664152550.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664152550.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wyeth Research, 02140, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Wyeth Research, 02140, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berkenblit", 
        "givenName": "Anna", 
        "id": "sg:person.01113347206.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113347206.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wyeth Research, 02140, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Wyeth Research, 02140, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thiele", 
        "givenName": "Alexandra", 
        "id": "sg:person.01055761716.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055761716.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wyeth Research, 02140, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Wyeth Research, 02140, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krygowski", 
        "givenName": "Mizue", 
        "id": "sg:person.01172210316.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172210316.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wyeth Research, 02140, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Wyeth Research, 02140, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Strahs", 
        "givenName": "Andrew", 
        "id": "sg:person.01306436716.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306436716.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wyeth Research, 02140, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Wyeth Research, 02140, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feingold", 
        "givenName": "Jay", 
        "id": "sg:person.0631146016.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631146016.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.249335.a", 
          "name": [
            "Department of Medical Oncology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hudes", 
        "givenName": "Gary", 
        "id": "sg:person.0634255670.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634255670.31"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.onc.1201983", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006110647", 
          "https://doi.org/10.1038/sj.onc.1201983"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/1727", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011959049", 
          "https://doi.org/10.1038/1727"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-02-20", 
    "datePublishedReg": "2009-02-20", 
    "description": "Purpose Exploratory subgroup analyses from the phase 3 global advanced renal cell carcinoma (ARCC) trial were conducted to assess the influence of tumor histology on outcome of patients treated with temsirolimus (Torisel\u2122) or interferon-\u03b1 (IFN). Patients and methods Patients with ARCC including clear cell and other types such as papillary and chromophobe histologies received either IFN (3\u00a0million units [MU] subcutaneously three times weekly, escalating to 18\u00a0MU) or temsirolimus (25\u00a0mg intravenously weekly). Results Approximately 80% of patients had clear cell and 20% of patients had other histologies, the majority of which were papillary. Patients with clear cell and other RCC histologies, treated with temsirolimus, demonstrated comparable median overall and progression-free survival. In contrast, patients with other RCC histologies, treated with IFN, demonstrated shorter median overall and progression-free survival than patients with clear cell RCC. Hazard ratios for death for treatment with temsirolimus versus IFN were less than 1 for patients regardless of tumor histology. For patients treated with temsirolimus, 59% with clear cell and 68% with other RCC histologies experienced tumor reductions. For patients treated with IFN, 35% with clear cell and 14% with other RCC histologies had tumor reductions. However, temsirolimus did not appear to improve the objective response rate compared to IFN. Temsirolimus resulted in a superior clinical benefit rate compared with IFN, regardless of tumor histology. Conclusion Temsirolimus appears to be efficacious in patients with clear cell and non-clear cell histologies and can, therefore, be used for the treatment of all types of RCC.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12032-009-9177-0", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "26"
      }
    ], 
    "keywords": [
      "outcomes of patients", 
      "progression-free survival", 
      "tumor histology", 
      "RCC histology", 
      "clear cells", 
      "tumor reduction", 
      "non-clear cell histology", 
      "advanced renal cell carcinoma", 
      "effect of temsirolimus", 
      "objective response rate", 
      "clinical benefit rate", 
      "different tumor histologies", 
      "exploratory subgroup analysis", 
      "renal cell carcinoma", 
      "clear cell RCC", 
      "chromophobe histology", 
      "Methods Patients", 
      "cell histology", 
      "cell carcinoma", 
      "subgroup analysis", 
      "benefit rate", 
      "cell RCC", 
      "temsirolimus", 
      "patients", 
      "types of RCC", 
      "response rate", 
      "IFN", 
      "histology", 
      "interferon", 
      "survival", 
      "outcomes", 
      "cells", 
      "RCC", 
      "treatment", 
      "carcinoma", 
      "trials", 
      "death", 
      "rate", 
      "reduction", 
      "majority", 
      "types", 
      "contrast", 
      "effect", 
      "ARCC", 
      "hazards", 
      "analysis", 
      "results", 
      "influence"
    ], 
    "name": "Effect of temsirolimus versus interferon-\u03b1 on outcome of patients with advanced renal cell carcinoma of different tumor histologies", 
    "pagination": "202-209", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015825260"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-009-9177-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19229667"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-009-9177-0", 
      "https://app.dimensions.ai/details/publication/pub.1015825260"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_487.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12032-009-9177-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-009-9177-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-009-9177-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-009-9177-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-009-9177-0'


 

This table displays all metadata directly associated to this object as RDF triples.

235 TRIPLES      21 PREDICATES      85 URIs      75 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-009-9177-0 schema:about N2d61a2a71c674af5acc1240f91348094
2 N4d12cd2bff7d4ed084591e19e34a29e5
3 N6786c419dd9d40b0a5ec5a5c767fd42e
4 N6e0f4c3f5b2046feab76f161c777b317
5 N77cdaed427d147e28407422e057152ec
6 N9859645ceeeb4e059b80305da80599a9
7 Nab11d7882bb142c784fc88e76112e4d9
8 Nb1e1a9fa23f54ab3833f4406fc3ba843
9 Nc457bd589a5644549d98d106df9bde0f
10 Nedbf4ebff03b4b54b0c32512f0254c5d
11 anzsrc-for:11
12 anzsrc-for:1112
13 schema:author N16cec1c724a94bb9a797d9d9a4efc9d5
14 schema:citation sg:pub.10.1038/1727
15 sg:pub.10.1038/sj.onc.1201983
16 schema:datePublished 2009-02-20
17 schema:datePublishedReg 2009-02-20
18 schema:description Purpose Exploratory subgroup analyses from the phase 3 global advanced renal cell carcinoma (ARCC) trial were conducted to assess the influence of tumor histology on outcome of patients treated with temsirolimus (Torisel™) or interferon-α (IFN). Patients and methods Patients with ARCC including clear cell and other types such as papillary and chromophobe histologies received either IFN (3 million units [MU] subcutaneously three times weekly, escalating to 18 MU) or temsirolimus (25 mg intravenously weekly). Results Approximately 80% of patients had clear cell and 20% of patients had other histologies, the majority of which were papillary. Patients with clear cell and other RCC histologies, treated with temsirolimus, demonstrated comparable median overall and progression-free survival. In contrast, patients with other RCC histologies, treated with IFN, demonstrated shorter median overall and progression-free survival than patients with clear cell RCC. Hazard ratios for death for treatment with temsirolimus versus IFN were less than 1 for patients regardless of tumor histology. For patients treated with temsirolimus, 59% with clear cell and 68% with other RCC histologies experienced tumor reductions. For patients treated with IFN, 35% with clear cell and 14% with other RCC histologies had tumor reductions. However, temsirolimus did not appear to improve the objective response rate compared to IFN. Temsirolimus resulted in a superior clinical benefit rate compared with IFN, regardless of tumor histology. Conclusion Temsirolimus appears to be efficacious in patients with clear cell and non-clear cell histologies and can, therefore, be used for the treatment of all types of RCC.
19 schema:genre article
20 schema:isAccessibleForFree false
21 schema:isPartOf N60d333390c414af99e03cd931ca21656
22 N852ab1bb789e45878b5d778e690a4a44
23 sg:journal.1094524
24 schema:keywords ARCC
25 IFN
26 Methods Patients
27 RCC
28 RCC histology
29 advanced renal cell carcinoma
30 analysis
31 benefit rate
32 carcinoma
33 cell RCC
34 cell carcinoma
35 cell histology
36 cells
37 chromophobe histology
38 clear cell RCC
39 clear cells
40 clinical benefit rate
41 contrast
42 death
43 different tumor histologies
44 effect
45 effect of temsirolimus
46 exploratory subgroup analysis
47 hazards
48 histology
49 influence
50 interferon
51 majority
52 non-clear cell histology
53 objective response rate
54 outcomes
55 outcomes of patients
56 patients
57 progression-free survival
58 rate
59 reduction
60 renal cell carcinoma
61 response rate
62 results
63 subgroup analysis
64 survival
65 temsirolimus
66 treatment
67 trials
68 tumor histology
69 tumor reduction
70 types
71 types of RCC
72 schema:name Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
73 schema:pagination 202-209
74 schema:productId N49d19caa75144467b875c0ba93a31edd
75 N5ae53564986543e38e4cf033275907da
76 N631c52647cd34ffcbff216bb45d23665
77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015825260
78 https://doi.org/10.1007/s12032-009-9177-0
79 schema:sdDatePublished 2022-09-02T15:54
80 schema:sdLicense https://scigraph.springernature.com/explorer/license/
81 schema:sdPublisher N0a98b61ff8194e9191e4fa103f1fb95e
82 schema:url https://doi.org/10.1007/s12032-009-9177-0
83 sgo:license sg:explorer/license/
84 sgo:sdDataset articles
85 rdf:type schema:ScholarlyArticle
86 N047162bfec62461abcf2a6d4adac6b1b rdf:first sg:person.0664152550.77
87 rdf:rest Na659f06adc534cd59df03cafc8737db2
88 N0a98b61ff8194e9191e4fa103f1fb95e schema:name Springer Nature - SN SciGraph project
89 rdf:type schema:Organization
90 N16cec1c724a94bb9a797d9d9a4efc9d5 rdf:first sg:person.0760406720.36
91 rdf:rest N7dba48cbef7644a197fb86d9869b8995
92 N2d61a2a71c674af5acc1240f91348094 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Treatment Outcome
94 rdf:type schema:DefinedTerm
95 N49d19caa75144467b875c0ba93a31edd schema:name dimensions_id
96 schema:value pub.1015825260
97 rdf:type schema:PropertyValue
98 N4d12cd2bff7d4ed084591e19e34a29e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Male
100 rdf:type schema:DefinedTerm
101 N526a530e6aa6440db66698a5ec34a3c5 rdf:first sg:person.01306436716.70
102 rdf:rest N633afa198f514913994977479adebb47
103 N553cbd79368f474fae19bc5d075afe2f rdf:first sg:person.01172210316.76
104 rdf:rest N526a530e6aa6440db66698a5ec34a3c5
105 N5ae53564986543e38e4cf033275907da schema:name doi
106 schema:value 10.1007/s12032-009-9177-0
107 rdf:type schema:PropertyValue
108 N60d333390c414af99e03cd931ca21656 schema:volumeNumber 26
109 rdf:type schema:PublicationVolume
110 N631c52647cd34ffcbff216bb45d23665 schema:name pubmed_id
111 schema:value 19229667
112 rdf:type schema:PropertyValue
113 N633afa198f514913994977479adebb47 rdf:first sg:person.0631146016.30
114 rdf:rest Nf330d05b4e994279b3ce557b22d17cbb
115 N6786c419dd9d40b0a5ec5a5c767fd42e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Interferon-alpha
117 rdf:type schema:DefinedTerm
118 N6e0f4c3f5b2046feab76f161c777b317 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Carcinoma, Renal Cell
120 rdf:type schema:DefinedTerm
121 N77cdaed427d147e28407422e057152ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Kidney Neoplasms
123 rdf:type schema:DefinedTerm
124 N7dba48cbef7644a197fb86d9869b8995 rdf:first sg:person.0762337214.67
125 rdf:rest Ne39c9273118744cda323ee4257165a83
126 N852ab1bb789e45878b5d778e690a4a44 schema:issueNumber 2
127 rdf:type schema:PublicationIssue
128 N9859645ceeeb4e059b80305da80599a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Antineoplastic Agents
130 rdf:type schema:DefinedTerm
131 Na402e167351d41358215118f56142350 rdf:first sg:person.01055761716.50
132 rdf:rest N553cbd79368f474fae19bc5d075afe2f
133 Na659f06adc534cd59df03cafc8737db2 rdf:first sg:person.01113347206.34
134 rdf:rest Na402e167351d41358215118f56142350
135 Nab11d7882bb142c784fc88e76112e4d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Female
137 rdf:type schema:DefinedTerm
138 Nb1e1a9fa23f54ab3833f4406fc3ba843 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Middle Aged
140 rdf:type schema:DefinedTerm
141 Nc457bd589a5644549d98d106df9bde0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Sirolimus
143 rdf:type schema:DefinedTerm
144 Ne39c9273118744cda323ee4257165a83 rdf:first sg:person.0656541200.82
145 rdf:rest N047162bfec62461abcf2a6d4adac6b1b
146 Nedbf4ebff03b4b54b0c32512f0254c5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Humans
148 rdf:type schema:DefinedTerm
149 Nf330d05b4e994279b3ce557b22d17cbb rdf:first sg:person.0634255670.31
150 rdf:rest rdf:nil
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
155 schema:name Oncology and Carcinogenesis
156 rdf:type schema:DefinedTerm
157 sg:journal.1094524 schema:issn 1357-0560
158 1559-131X
159 schema:name Medical Oncology
160 schema:publisher Springer Nature
161 rdf:type schema:Periodical
162 sg:person.01055761716.50 schema:affiliation grid-institutes:grid.410513.2
163 schema:familyName Thiele
164 schema:givenName Alexandra
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055761716.50
166 rdf:type schema:Person
167 sg:person.01113347206.34 schema:affiliation grid-institutes:grid.410513.2
168 schema:familyName Berkenblit
169 schema:givenName Anna
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113347206.34
171 rdf:type schema:Person
172 sg:person.01172210316.76 schema:affiliation grid-institutes:grid.410513.2
173 schema:familyName Krygowski
174 schema:givenName Mizue
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172210316.76
176 rdf:type schema:Person
177 sg:person.01306436716.70 schema:affiliation grid-institutes:grid.410513.2
178 schema:familyName Strahs
179 schema:givenName Andrew
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306436716.70
181 rdf:type schema:Person
182 sg:person.0631146016.30 schema:affiliation grid-institutes:grid.410513.2
183 schema:familyName Feingold
184 schema:givenName Jay
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631146016.30
186 rdf:type schema:Person
187 sg:person.0634255670.31 schema:affiliation grid-institutes:grid.249335.a
188 schema:familyName Hudes
189 schema:givenName Gary
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634255670.31
191 rdf:type schema:Person
192 sg:person.0656541200.82 schema:affiliation grid-institutes:grid.239395.7
193 schema:familyName McDermott
194 schema:givenName David
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656541200.82
196 rdf:type schema:Person
197 sg:person.0664152550.77 schema:affiliation grid-institutes:grid.410425.6
198 schema:familyName Figlin
199 schema:givenName Robert A.
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664152550.77
201 rdf:type schema:Person
202 sg:person.0760406720.36 schema:affiliation grid-institutes:grid.240283.f
203 schema:familyName Dutcher
204 schema:givenName Janice P.
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760406720.36
206 rdf:type schema:Person
207 sg:person.0762337214.67 schema:affiliation grid-institutes:grid.416398.1
208 schema:familyName de Souza
209 schema:givenName Paul
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762337214.67
211 rdf:type schema:Person
212 sg:pub.10.1038/1727 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011959049
213 https://doi.org/10.1038/1727
214 rdf:type schema:CreativeWork
215 sg:pub.10.1038/sj.onc.1201983 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006110647
216 https://doi.org/10.1038/sj.onc.1201983
217 rdf:type schema:CreativeWork
218 grid-institutes:grid.239395.7 schema:alternateName Department of Oncology, Beth Israel Deaconess Medical Center, 02215, Boston, MA, USA
219 schema:name Department of Oncology, Beth Israel Deaconess Medical Center, 02215, Boston, MA, USA
220 rdf:type schema:Organization
221 grid-institutes:grid.240283.f schema:alternateName Montefiore Medical Center-North Division/New York Medical College, 600 East 233rd Street, 10466, Bronx, NY, USA
222 schema:name Montefiore Medical Center-North Division/New York Medical College, 600 East 233rd Street, 10466, Bronx, NY, USA
223 rdf:type schema:Organization
224 grid-institutes:grid.249335.a schema:alternateName Department of Medical Oncology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA
225 schema:name Department of Medical Oncology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA
226 rdf:type schema:Organization
227 grid-institutes:grid.410425.6 schema:alternateName Division of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 91010, Duarte, CA, USA
228 schema:name Division of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 91010, Duarte, CA, USA
229 rdf:type schema:Organization
230 grid-institutes:grid.410513.2 schema:alternateName Wyeth Research, 02140, Cambridge, MA, USA
231 schema:name Wyeth Research, 02140, Cambridge, MA, USA
232 rdf:type schema:Organization
233 grid-institutes:grid.416398.1 schema:alternateName Department of Medical Oncology, St. George Hospital, 2217, Kogarah, NSW, Australia
234 schema:name Department of Medical Oncology, St. George Hospital, 2217, Kogarah, NSW, Australia
235 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...